Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Randomized phase II trial of GOC plus panitumumab or bevacizumab in inoperable cholangiocarcinoma without KRAS mutations
2010-020385-13Phase 2Completed
- Sponsor
- Vejle Hospital
- Start
- Jun 2010
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised trial in cholangiocarcinoma (CCA) comparing GOC + panitumumab with GOC + bevacizumab (2 arms). Primary endpoint: Progression-free survival at 6 months. Started Jun 2010; status: completed.
02
Drugs
panitumumabbevacizumab
03
Conditions
cholangiocarcinoma (CCA)
Beyond the preview
Go deeper on 2010-020385-13.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-020385-13.